JW Pharmaceutical Corporation (001067.KS)

JW Pharmaceutical Corporation (001067.KS) — VMCI valuation read

001067.KS screens at VMCI 71/100, a 21-point gap above the broad-market sample median (50). For a mid-cap JW Pharmaceutical Corporation share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

001067.KS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 001067.KS trades at 16.0x earnings, 11% below the sector median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the sector group. Quality: ROIC of 12.0% sits 2.0pp above the sector median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 2.6x is the rate-sensitivity line to watch, which sets the rate-cycle exposure for JW Pharmaceutical Corporation.

001067.KS held flat 0.0% over the trailing 7 days, with a -23.0% read on a 30-day basis.